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Introduction {#sec1}
============

Cell-based advanced therapy medicinal products (ATMPs) have the potential to transform our health care systems, especially for patients with failing intrinsic tissue regeneration such as complex and large bone defects in compromised biological conditions ([@bib16]). The standard approach of this strategy typically includes: (1) donor cells to form tissues together with available host cells, (2) stimulatory factors to direct cellular processes, and (3) biomaterials to provide cells with 3D cues ([@bib27]). Despite major advances in the design, production and in vitro performance of ATMPs, only a fraction displays suitable characteristics for clinical translation ([@bib28]). Major reasons for this lack in clinical monetization of research efforts can be attributed to a poor design and lack of robust manufacturing protocols. In terms of the design, a biomimetic strategy inspired by developmental embryology provides a scientific foundation and offers key clues regarding the main players, sequences of events and 3D stimulatory cues in postnatal fracture healing ([@bib29], [@bib22], [@bib47], [@bib25]). Previous reports established that large bone defects mainly heal through the formation of an intermediate cartilaginous callus ([@bib16]). Consequently, in order to mimic the native healing process of a large long-bone defect, a cell-based ATMP was designed to develop along the endochondral route. However, the classical cell source for bone repair used today is a bone marrow aspirate from the iliac crest. Yet, bone marrow-derived cells exclusively contribute to fracture healing by direct bone formation ([@bib9]). In consequence, periosteum-derived cells (PDCs), the main contributing cells in endochondral fracture healing, may be a more clinically relevant cell source ([@bib9], [@bib10]). Moreover, PDCs have shown osteochondrogenic potential both in vitro and in vivo ([@bib12]). As stimulatory factors, bone morphogenetic proteins (BMPs) are of relevance due to their crucial role in PDC-mediated fracture healing ([@bib46], [@bib8]). Moreover, specific BMP ligands have been shown to induce human PDC (hPDC)-mediated ectopic ossicle formation ([@bib5]).

Approval for clinical applications of BMP-2 and BMP-7 has already been obtained. However, their use has been associated with unpredictable bone formation due to a number of reasons, including the delivery of the supraphysiological levels required for progenitor cell recruitment ([@bib44], [@bib38]). In vitro primed cell-based ATMPs could overcome this hurdle by delivery of the crucial number of progenitors required, appropriately primed in vitro to regenerate the damaged tissue in vivo. However, until now, in vitro stimulation of progenitor cells for in vivo tissue regeneration has been challenging. Long-term in vitro stimulated cells often fail to integrate with the host, likely due to the maturity of the tissue ([@bib50]). Shorter priming periods on the other hand, seem not to be sufficient in terms of clinically relevant results ([@bib19]). A potential reason for this can be that the in vitro priming is carried out in medium containing serum ([@bib41]). Indeed, serum contains an undefined and variable range of factors such as cytokines and inhibitors that bind to cell surface receptors. In consequence, batch-to-batch variability significantly affects the characteristics of cell-based implants, leading to unpredictable behavior and outcomes ([@bib24], [@bib3]).

It was therefore hypothesized that serum-free pre-conditioning of hPDCs prior to growth factor treatment could improve the cellular response. A chemically defined serum-free pre-conditioning regime of hPDCs was developed that led to an adapted progenitor cell population with improved differentiation capacity. When assembling the pre-conditioned cells into microaggregates, mimicking cellular condensations by providing biomimetic 3D cues, and simultaneously treating them with BMP-2, cell specification toward the osteochondrogenic lineages was observed. Interestingly, physiologically relevant levels of autocrine and paracrine growth factors were secreted by the fate-steered, engineered microtissues. In vivo, the self-sustained implant proceeded to mature into endochondral bone, recapitulating long-bone fracture healing. We anticipate that the proposed serum-free strategy can be translated in a wide array of applications within the field of regenerative medicine.

Results {#sec2}
=======

Pre-conditioning Induces a Cellular Identity Shift toward a CD34^+^ Progenitor {#sec2.1}
------------------------------------------------------------------------------

To define the culture conditions that maintained cell viability without enhancing proliferation, hPDCs were cultured for 6 days in a chemically defined medium (CDM) and compared with hPDCs cultured in growth medium (GM) containing 10% fetal bovine serum. After 24 hr, as well as after 6 days of culture, cells in CDM showed no cell proliferation compared with GM-cultured cells ([Figure 1](#fig1){ref-type="fig"}A). However, after 6 days, elevated DNA contents per cell were seen in pre-conditioned cells ([Figure 1](#fig1){ref-type="fig"}B). To investigate whether adaptations in the cell cycle were caused, expression levels of cell cycle markers cyclin-dependent kinase 1 (*CDK1*), cyclin E1 (*CCNE1*), and baculoviral inhibitor of apoptosis repeat-containing 5 (*BIRC5*) were determined. Expression of *CDK1*, essential for cell cycle progression during S and G2 phases, displayed a 6-fold upregulation in pre-conditioned cells ([Figure 1](#fig1){ref-type="fig"}C). Similarly, a 7-fold increased transcript level of *CCNE1*, required for G1/S transition was found ([Figure 1](#fig1){ref-type="fig"}D). Interestingly, a 10-fold increased level of *BIRC5*, a negative regulator of apoptosis during the G2/M phase was also seen in pre-conditioned cells ([Figure 1](#fig1){ref-type="fig"}E). To further investigate changes in cellular identity, flow cytometry was performed to characterize the expression of conventional mesenchymal stem cell markers ([Figure 1](#fig1){ref-type="fig"}F). It was shown that over 97% of cells grown in GM were positive for CD73, CD90, and CD105, whereas only 81% of cells cultured in CDM were positive for CD105. Cells from both conditions were negative for CD14, CD20, and CD45 ([Figure S1](#mmc1){ref-type="supplementary-material"}A), but 70% of the CDM pre-conditioned cells displayed positivity for CD34 ([Figure 1](#fig1){ref-type="fig"}F), a phenomenon that was not seen in human bone marrow stromal cells ([Figure S1](#mmc1){ref-type="supplementary-material"}B). Kinetic studies by mRNA transcript analysis and flow cytometry revealed a gradual increase in *CD34* expression as well as in the amount of receptors per cell during pre-conditioning ([Figures 1](#fig1){ref-type="fig"}G and 1H). The opposite trend was seen for CD105, where pre-conditioning led to a decreased expression of *CD105* cells as well as a reduced amount of receptors per cell ([Figures 1](#fig1){ref-type="fig"}I and 1J). Of note, mRNA transcript levels of *CD34* displayed a 70- and 20-fold higher expression in hPDCs from individual donors at passage zero (p0) compared with GM-expanded cells at passage 6 (p6), respectively ([Figure S1](#mmc1){ref-type="supplementary-material"}C). In addition, CDM pre-conditioning led to increased cell size and less granularity ([Figure S1](#mmc1){ref-type="supplementary-material"}D). However, no significant aberrations were observed in karyotype analysis ([Figure S1](#mmc1){ref-type="supplementary-material"}E).

To investigate whether the pre-conditioning regimen may lead to an enhanced BMP response, mRNA transcript analysis of BMP type 1 and type 2 receptors was performed. CDM pre-conditioned cells displayed an increased expression of BMP type 1 (*ALK1*, *ALK2*, *ALK3*, and *ALK6*) and type 2 (*BMPR2*, *ACVR2a*, and *ACVR2b*) receptors, in comparison with standard cultured cells ([Figure 1](#fig1){ref-type="fig"}K). To further characterize the CDM-grown cells, mRNA transcript analysis displayed elevated expression of secreted factors relevant to bone formation: a 10-, 12-, and 4.6-fold increase for basic fibroblast growth factor (*FGF-2*), vascular endothelial growth factor (*VEGF*), and matrix metallopeptidase 9 (*MMP9*) expression, respectively ([Figure 1](#fig1){ref-type="fig"}L). These results were also confirmed on the protein level through an ELISA assay on conditioned medium ([Figure 1](#fig1){ref-type="fig"}M). Combined, these data indicate that the serum-free pre-conditioning led to an adapted cellular phenotype specific for hPDCs. Reduced positivity for MSC markers was correlated to increased positivity for CD34 and elevated expression of BMP receptors, identifying a switch in cellular identity.

Enhanced Effect of BMP-2-Induced Differentiation in Pre-conditioned hPDCs {#sec2.2}
-------------------------------------------------------------------------

Next, we set out to investigate whether these changes would translate into distinct responses upon BMP treatment. hPDCs were pre-conditioned in CDM or GM followed by 24 hr, or 3 or 6 days of BMP-2 stimulation in CDM. After 6 days, morphological differences between the two conditions were seen ([Figure 2](#fig2){ref-type="fig"}A). Cells pre-conditioned under serum-containing conditions displayed a heterogeneous cell population with a fraction possessing a polygonal shape resembling differentiating cells (black arrows). Interestingly, BMP-2-stimulated cells pre-conditioned in CDM displayed a more homogeneous cell morphology in which the majority of the cells exhibited a polygonal shape (black arrows). This phenomenon was associated with an increase in alkaline phosphatase (ALP) activity since a 3- and 1.5-fold increase was observed after 3 and 6 days of BMP stimulation, respectively ([Figure 2](#fig2){ref-type="fig"}B). To confirm the differentiation stage of the cells, mRNA transcripts were analyzed. After 24 hr of BMP-2 stimulation, a 2-fold upregulation of *SRY* (sex determining region *Y*)-*Box* 9 (*SOX9*) was seen in BMP-2 stimulated samples and this effect was further elevated to over 10-fold in day 3 and day 6 samples ([Figure 2](#fig2){ref-type="fig"}C). Moreover, CDM pre-conditioned cells displayed a 1.6- and 2-fold elevated expression compared with serum conditions in day 3 and 6 samples. Similarly, the osteogenic marker Osterix (*OSX*) was upregulated in CDM pre-conditioned cells with a 1.6- and 1.9-fold increase after 3 and 6 days, respectively ([Figure 2](#fig2){ref-type="fig"}D). In support of the enhanced osteochondrogenic differentiation profiles of CDM pre-conditioned cells, analysis of collagen type 2a (*COLL2A1)*, collagen type 10 (*COLL10A1*), runt-related transcription factor 2 (*RUNX2)*, and collagen type 1 (*COLL1A1*) is presented in [Figure S2](#mmc1){ref-type="supplementary-material"}A. Activated BMP signaling was confirmed by inhibitor of differentiation 1 (*ID1*) expression, a 2.5- and 2-fold higher expression was seen in CDM pre-conditioned cells after 3 and 6 days, respectively ([Figure 2](#fig2){ref-type="fig"}E).

Pre-conditioned Cells Undergo Osteochondrogenic Differentiation {#sec2.3}
---------------------------------------------------------------

The mRNA transcript analysis suggested a robust chondrogenic as well as osteogenic differentiation in cells pre-conditioned in CDM. To define whether there was a subpopulation of cells that differentiated toward a specific lineage, a combined immunohistochemistry (IHC) for SOX9 (red), OSX (green), and DAPI (blue) was performed. Cells displayed similar positivity for SOX9 in both BMP-2-stimulated conditions, but a larger fraction of OSX-positive cells in CDM pre-conditioned cells, mainly in combination with SOX9 positivity ([Figure 2](#fig2){ref-type="fig"}F). Quantification of merged images confirmed elevated positivity for both markers in CDM pre-conditioned cells followed by BMP-2 stimulation ([Figure 2](#fig2){ref-type="fig"}G). Of note, the enhanced BMP response in CDM pre-conditioned cells was not specific for BMP-2. In fact, this was consistent for a range of BMPs including BMP-4, -6, -7, -9, and GDF5. Upon mRNA transcript analysis of *SOX9* and *OSX*, a more than 2-fold increase was seen for all BMPs in cells pre-conditioned in CDM ([Figures 2](#fig2){ref-type="fig"}H and 2I). A similar phenomenon was seen for the BMP target gene *ID1* ([Figure 2](#fig2){ref-type="fig"}J). The elevated osteochondrogenic differentiation was further supported by analysis of aggrecan (*ACAN*), osteocalcin (*OCN*), distal-less homeobox 5 (*DLX5*), *BMP-2*, and *VEGF* ([Figure S2](#mmc1){ref-type="supplementary-material"}B). The effect of CDM pre-conditioning was confirmed in young and adult donors, and presented in [Supplemental Information](#app2){ref-type="sec"} ([Figure S3](#mmc1){ref-type="supplementary-material"}A--S3G). Upon ectopic in vivo implantation for 3 weeks, CDM pre-conditioning followed by BMP-2 stimulation led to elevated cartilaginous matrix formation compared with GM-stimulated cells ([Figure S4](#mmc1){ref-type="supplementary-material"}). These data show that serum-free pre-conditioning uniquely leads to an increased differentiation response to several BMP ligands. This effect is independent of donor gender or age and in vitro findings were translated in the in vivo setting.

Enhanced Differentiation due to an Altered BMP Pathway Activation {#sec2.4}
-----------------------------------------------------------------

Western blot analysis of the pre-conditioned cells after 60 min of BMP-2 stimulation displayed an altered BMP signaling pathway activation compared with GM control ([Figures 3](#fig3){ref-type="fig"}A--3E). Quantification displayed elevated phosphorylation of the SMAD1/5/8 complex and p38 in the CDM pre-conditioned cells, while cells stimulated under GM conditions displayed phosphorylation of ERK1/2 and p38 ([Figures 3](#fig3){ref-type="fig"}F--3H). Since BMP signaling is known to crosstalk with downstream regulators of Wnt and transforming growth factor β, the activation of β-catenin and the SMAD2/3 complex was investigated. It was shown that BMP stimulation under GM conditions led to an increased level of active β-catenin, while CDM pre-conditioned cells displayed phosphorylation of the SMAD2/3 complex ([Figures 3](#fig3){ref-type="fig"}I and 3J). Together, these data confirm that the enhanced osteochondrogenic differentiation observed in the CDM pre-conditioned cells was associated with an altered downstream signaling activation.

The CD34^+^ Cell Population Displayed a More Potent Osteochondrogenic Potential {#sec2.5}
-------------------------------------------------------------------------------

To investigate whether it was the CD34^+^ cell population that was more BMP responsive, pre-conditioned CD34^+^ cells were sorted and compared with the total CDM population. On the mRNA transcript level, elevated CD34 expression was confirmed ([Figure 3](#fig3){ref-type="fig"}K). Interestingly, an upregulated expression of BMP receptors *ALK1* and *ALK6* was confirmed, whereas an upregulated trend was detected for *ALK2* and *BMPR2*, and no difference was found for *ALK3* ([Figure 3](#fig3){ref-type="fig"}L). Upon BMP-2 stimulation, the CD34^+^ population displayed a 2- and 5-fold elevated expression of *SOX9* and *OSX*, respectively ([Figure 3](#fig3){ref-type="fig"}M). Cluster analysis displayed a correlation between elevated *CD34*, *ALK1*, *ALK2*, *ALK6*, *BMRP2*, *SOX9*, and *OSX* expression ([Figure 3](#fig3){ref-type="fig"}N), and specific grouping of the CD34^+^ population was depicted in a constellation plot ([Figure 3](#fig3){ref-type="fig"}O). Combined, these data indicate that the increased osteochondrogenic response is related to the CD34^+^ cell population.

Bioinspired 3D Aggregation and BMP-2 Stimulation Reduce Stemness and Cell Size {#sec2.6}
------------------------------------------------------------------------------

Cellular condensations precede limb bud development and therefore aggregation was investigated in order to enhance cell specification in hPDCs by providing biomimetic 3D cues. Aggregate size affects mechanical cues, nutrient flux, and cell-cell interaction forces. Optimal aggregate size was determined through an in vitro screening of 50, 100, and 250 hPDCs/aggregate. Cell aggregation was induced on pre-conditioned cells with or without BMP-2 stimulation for 6 days, after which the samples were analyzed by microscopy, mRNA transcript analysis, histology, and IHC. 2D-cultured cells were included as a control. Bright-field images showed that uniform aggregates were formed in the 100 and 250 cell aggregate size ([Figure S5](#mmc1){ref-type="supplementary-material"}A). Next, the influence of aggregation and BMP-2 stimulation on the MSC markers CD73, CD90, and CD105 was investigated by flow cytometry ([Figure 4](#fig4){ref-type="fig"}A). The analysis of CD73 showed a reduced positivity from 96% to below 80% in aggregated cells in the presence of BMP-2. This effect was even more pronounced for CD90 with less than 45% positivity. The largest reduction was seen when analyzing CD105 expression: only 19% of the cells cultured in an aggregate system and stimulated with BMP-2 were positive compared with 96% in only aggregated cells. Moreover, aggregation induced a reduction in cell size compared with both the control and BMP-2-stimulated cells in 2D ([Figure S5](#mmc1){ref-type="supplementary-material"}B). These data indicate that an aggregation-dependent effect on the CD34-enriched hPDC population was induced, further enhanced in combination with BMP-2 stimulation.

Aggregation and BMP-2 Treatment Synergistically Enhance In Vitro Osteochondrogenic Differentiation {#sec2.7}
--------------------------------------------------------------------------------------------------

Upon mRNA transcript analysis, BMP-2 stimulation induced an elevated expression of the chondrogenic markers *SOX9*, *COLL2A1*, and *ACAN* ([Figure 4](#fig4){ref-type="fig"}B), and the largest increase in expression was found in cells stimulated in 2D. Upon analysis of osteogenic markers *RUNX2*, *ALP*, and *OSX*, a synergistic effect of aggregation in combination with BMP-2 stimulation was seen, which was further increased with aggregate size ([Figure 4](#fig4){ref-type="fig"}C). The upregulated differentiation profile could be correlated to the expression of the transcriptional regulator *DLX5*, the BMP marker gene *ID1*, and the angiogenic marker *VEGF* ([Figure 4](#fig4){ref-type="fig"}D). Next, the gene expression data were confirmed on the protein level by IHC for SOX9 (red), OSX (green), and DAPI (blue) ([Figure S6](#mmc1){ref-type="supplementary-material"}A). Histology for H&E, Alcian blue (AB) and alizarin red displayed the initiation of matrix formation in the in vitro stimulated microtissues, depicted in stained sections of 250 hPDCs/aggregate ([Figure S6](#mmc1){ref-type="supplementary-material"}B). These data confirmed the induction of osteochondrogenic cell specification induced by the 3D environment, in which the aggregate size steered differentiation in combination with BMP-2.

In Vivo Ectopic Tissue Formation {#sec2.8}
--------------------------------

Based on the in vitro analysis, the size of 250 cells/aggregate was selected for in vivo evaluation combined with or without simultaneous BMP-2 stimulation in parallel to 2D-stimulated cultures. In addition, 2D cultures stimulated with BMP-2 for 6 days followed by 24 hr of aggregation in the absence of BMP-2 were included in order to evaluate the combined as well as the individual effects of aggregation and BMP stimulation. Upon analysis of implants harvested after 1 week, H&E staining displayed microvessel formation (black arrows) which was shown to be 2-fold higher in samples treated with BMP-2. This effect was synergistic when combined with aggregation ([Figures 5](#fig5){ref-type="fig"}A and 5E). An AB staining revealed the deposition of cartilaginous matrix, rich in GAG content, in BMP-2-treated aggregates (black arrows) ([Figure 5](#fig5){ref-type="fig"}B), confirmed by Masson\'s trichrome (MT) stain, which displayed a more mature matrix tissue with a denser collagen content (black arrows) ([Figure 5](#fig5){ref-type="fig"}C). IHC for p-SMAD1/5/8 showed active BMP signaling in explants that were cultivated in the presence of BMP-2 or aggregated, depicted by brown nuclei (black arrows) ([Figure 5](#fig5){ref-type="fig"}D). When combined, the number of positive nuclei was further increased (black arrows). These data were confirmed by quantification of positive nuclei normalized to the total number of nuclei ([Figure 5](#fig5){ref-type="fig"}F). Due to the active BMP signaling, analysis of endogenous BMP-2 production was investigated by ELISA in conditioned medium at the time of implantation ([Figure 5](#fig5){ref-type="fig"}G). The combined effect of BMP-2 stimulation and aggregation displayed 1.5-fold higher BMP-2 protein levels in conditioned medium compared with fresh stimulation medium. This finding was further confirmed by enhanced mRNA transcript levels of BMP-2 expression at the time of implantation ([Figure 5](#fig5){ref-type="fig"}H).

After 3 weeks, H&E staining displayed the presence of hypertrophic chondrocytes in BMP-2-stimulated aggregates (3D) (black arrows), a phenomenon that was not seen in 2D stimulated cells followed by aggregation (2D-3D) ([Figure 6](#fig6){ref-type="fig"}A). An AB stain confirmed the formation of a dense matrix rich in GAGs (white arrows) ([Figure 6](#fig6){ref-type="fig"}B). These findings were further supported by an MT staining ([Figure 6](#fig6){ref-type="fig"}C). To analyze remodeling of the cartilaginous matrix, tartrate-resistant acid phosphatase (TRAP) staining was performed, which showed positive areas in close vicinity to GAG-rich areas and hypertrophic chondrocytes (black arrows) ([Figure 6](#fig6){ref-type="fig"}D). Upon quantification, the BMP-2-stimulated aggregates displayed a 2-fold higher percentage of TRAP^+^ area ([Figure 6](#fig6){ref-type="fig"}E). Remodeling of the cartilage intermediate was further confirmed by IHC for DIPEN, the cryptic epitope of ACAN, typically exposed upon its degradation (black arrows) ([Figure 6](#fig6){ref-type="fig"}F). To further characterize the cartilaginous tissue, IHC for S100 confirmed a 6-fold higher positive area in BMP-2-stimulated aggregates (black arrows) ([Figures 6](#fig6){ref-type="fig"}G and 6H). Furthermore, a mature cartilaginous tissue was confirmed by IHC for Indian hedgehog (Ihh), expressed by (pre)hypertrophic chondrocytes (black arrows) ([Figures 6](#fig6){ref-type="fig"}I and 6J).

After 6 weeks, the 3D stimulated tissue intermediate had further developed along the endochondral route to form ectopic mineralized tissue ([Figure 6](#fig6){ref-type="fig"}K). Formation of bone ossicles were confirmed through H&E and MT staining. Bone (black arrows) and bone marrow (red arrows) were observed as well as zones of mature bone (green arrows) ([Figure 6](#fig6){ref-type="fig"}L). Active remodeling (blue arrows) was indicated by a TRAP staining while contribution of the implanted cells was confirmed by IHC specific for human osteocalcin (hOCN). These data confirm the in vivo maturation and reveal that the combined approach of cell aggregation and exposure to BMP-2 induced in vivo tissue development in a process closely resembling endochondral bone formation.

Healing of a Critical Size Long-Bone Defect {#sec2.9}
-------------------------------------------

Based on the ectopic endochondral development of the in vitro primed microtissues, the orthotopic behavior was next assessed in a critical size tibia defect in immunodeficient mice. Upon transplantation, the in vitro BMP-2-stimulated aggregates led to bridging within 4 weeks as assessed by X-ray analysis in five of six animals ([Figure 7](#fig7){ref-type="fig"}A). Non-unions were confirmed in four of five controls up to 8 weeks after the creation of the defects. Full bridging by a mineralized matrix at 4 and 8 weeks was confirmed by nano-computed tomography scanned explants ([Figure 7](#fig7){ref-type="fig"}B). Qualitative analysis was assessed by histology and IHC. H&E and Safranin O/fast green staining revealed a cartilage intermediate 2 weeks post implantation ([Figures 7](#fig7){ref-type="fig"}C and 7D). Hypertrophic chondrocytes were present (gray arrows) in the center of the cartilaginous callus, whereas a mineralized tissue had started to form in the periphery, the latter being visualized by MT staining (black arrows) ([Figure 7](#fig7){ref-type="fig"}E). The early cartilage intermediate displayed positivity for TRAP (blue arrows), suggesting remodeling of the mineralized cartilaginous intermediate, a process that was maintained at week 4 but decreased at week 8 ([Figure 7](#fig7){ref-type="fig"}F). Moreover, the cartilage callus displayed positivity for hOCN, depicted by a brown stain (white arrows), confirming the contribution of donor cells ([Figure 7](#fig7){ref-type="fig"}G). At 4 weeks, a fully mineralized bridging was observed, where the MT staining showed more mature mineralized zones, indicated by red zones (yellow arrows) ([Figure 7](#fig7){ref-type="fig"}E). This mineralized tissue stained positive for hOCN (white arrows) ([Figure 7](#fig7){ref-type="fig"}G). After 8 weeks, the mineralized matrix displayed more zones of mature bone which was also confirmed to be positive for hOCN (white arrows) ([Figures 7](#fig7){ref-type="fig"}F and 7G). In addition, qualitative analysis confirmed the absence of cartilage or osseous tissue in control non-unions as well as a negative staining for hOCN ([Figures 7](#fig7){ref-type="fig"}C--7G). These data demonstrate a successful bridging of a critical size fracture by an in vitro primed cell-based construct.

Discussion {#sec3}
==========

Cell-based ATMPs represent an opportunity for the qualitative long-term cure of incapacitated organs or tissues lacking adequate intrinsic biological potential to heal ([@bib16]). Despite scientific breakthroughs, only a fraction of the developed ATMPs today reaches success in clinical translation for many reasons, including the poor design of the ATMP, modest outcomes in rigorous clinical trials, manufacturing challenges, and cost of goods ([@bib17]). To drive successful clinical translation, a deeper understanding of the basic biology that underlies (1) the mechanism of the healthy repair process that is failing and (2) the design of the engineered construct, is required ([@bib30]). As a driving force in developing a clinically effective ATMP for large long-bone defect healing, the choice of progenitor cells is of importance where the periosteum represents a relevant tissue source. Autologous hPDCs can be isolated at the site of the fracture without a second surgery. However, there are limitations in terms of the amount of tissue available. The use of allogenic cells may allow harvest of larger tissues depending on the donor, but comprises the risk of disease transmission and immune response ([@bib34]). Consequently, current cell culture protocols focus on achieving a fast and efficient expansion phase without an appreciation of maintenance of the progenitor potential.

In addition, recent findings indicate that the majority of in vitro expanded cells undergo apoptosis upon implantation ([@bib45]). A cause may be the need to instantly adjust to a compromised environment, since current culture conditions represent a rather non-physiological and abundant nutritional source. Optimized culture conditions for clinically relevant progenitors are therefore essential for the in vitro preparation of cell-based constructs and should maintain cell survival, allow efficient growth factor treatments without batch-to-batch variation, and meet the regulatory guidelines ([@bib13]).

We developed a serum-free pre-conditioning regime in a CDM in order to adapt/prepare progenitor cells for differentiation and the subsequent in vivo environment. Of note, pre-conditioning in CDM led to an increased DNA content per cell, but no cell proliferation or change in karyotype profile. This suggests the onset of endoreplication, a phenomenon where cells replicate the nuclear genome in the absence of cell division, leading to elevated DNA content and enhanced cell potential in order to save energy ([@bib14]). This was further supported by increased mRNA transcript levels of the cell cycle markers *CCNE1*, *CDK1*, and *BIRC5* ([@bib4], [@bib6], [@bib49]). Although the mechanism of endoreplication is not yet fully understood, studies in mice have shown improved adaptation to stress and/or limited energy sources, typically seen during tissue regeneration ([@bib37], [@bib43]). Although more studies are needed in order to elucidate whether cells from the periosteum adapt this mechanism after the initial proliferative burst in fracture healing, this may be a potential cause of their remarkable regenerative capacity ([@bib40]), a phenomenon partially replicated by the pre-conditioning.

Furthermore, a dramatic shift in MSC marker expression was seen, including an increased positivity for CD34 ([@bib48], [@bib20], [@bib26]). There is evidence that CD34 is a marker for diverse progenitors including MSCs ([@bib11]). In the current study, mRNA transcript levels of *CD34* were higher in freshly isolated hPDCs grown to confluency. This indicates that native progenitors from the periosteum may be CD34^+^, but the expression is lost upon in vitro expansion. This is in line with previous reports with murine bone marrow mononuclear progenitors, defined as a potent osteoprogenitor cell population, losing their CD34^+^ upon in vitro expansion ([@bib1]). Moreover, the CD34^+^ cell population displayed an enhanced expression and secretion of osteoprogenitor-secreted factors ([@bib31], [@bib23]). In addition, an elevated expression of BMP type 1 and 2 receptors was seen, suggesting the generation of a more BMP-responsive cell population ([@bib21]). In line with these findings, CDM pre-conditioned hPDCs displayed an earlier onset of, as well as an elevated osteochondrogenic response to BMP treatment, confirmed by BMP-2, -4, -6, -7, -9, and GDF5 stimulation. This improved differentiation potential could be correlated to the CD34^+^ cell population. In addition, an altered activation of downstream signaling pathways was confirmed in the CDM pre-conditioned cells, suggesting a potential mechanism to the more potent differentiation. Importantly, a change in cellular phenotype and improved differentiation potential was observed in cells isolated from donors of different gender and age, in line with previous reports on the osteochondrogenic capacity of PDCs ([@bib7]). Of note, a reduced response was seen in cells isolated from a 47-year-old female, which was associated with low expression levels of BMP receptors. Further screening of more samples will be required to determine whether this is a combined age- and gender-dependent phenomenon ([@bib36]). Since both an elevated osteogenic as well as chondrogenic differentiation was seen, IHC for SOX9 and OSX was performed to gain information at the single-cell level. Remarkably, CDM pre-conditioned cells displayed a positivity for both markers. Cell-fate studies have revealed that SOX9-expressing limb bud mesenchymal cells give rise to both chondrocytes and osteoblasts, where SOX9 expression precedes RUNX2 and OSX expression during limb bud development ([@bib2], [@bib35]). As a consequence, the combined SOX9 and OSX positivity may reflect the stage when cells enter the hypertrophic or early osteoblast stage and undergo a transition from SOX9^+^ to OSX^+^ cells. On the other hand, additional markers such as *ACAN*, *COLL10A1*, *RUNX2*, and *OCN* are also upregulated, further opening the possibility of cells undergoing a dual- or trans-differentiating pathway ([@bib51], [@bib52]). Nevertheless, the elevated differentiation capacity seen in vitro could be correlated to an elevated cartilaginous tissue production in vivo. To further investigate the in vivo potential, a biomimetic system in the form of cell aggregation was introduced ([@bib33], [@bib18]). Initially, an optimal size of the aggregate was determined and an increased aggregate size led to elevated expression of *RUNX2*, *ALP*, *OSX*, and *VEGF*. This could potentially be explained by the elevated forces exerted by the increased number of cells in the aggregates, which further steered differentiation toward the endochondral fate ([@bib39], [@bib32]). Upon ectopic assessment in vivo, a synergistic effect of aggregation and BMP-2 treatment displayed an enhanced microvessel ingrowth along with the presence of GAG-rich matrix and active BMP signaling. It can be speculated that this was due to endogenous BMP production suggested by an elevated BMP-2 protein secretion, further supported by elevated *BMP-2* expression on an mRNA transcript level. Therefore, the endogenous BMP secretion may further have contributed to in vivo endochondral bone formation ([@bib15], [@bib42]). After 3 weeks in vivo, the presence of hypertrophic chondrocytes, cartilage remodeling, and degradation was observed in constructs where simultaneous stimulation by aggregation and BMP-2 was applied. At week 6, these constructs had further developed into bone ossicles. Assessment in a critical size long-bone defect displayed successful bone bridging 4 weeks post transplantation. Qualitative analysis at 2 weeks displayed a process resembling endochondral bone healing with the contribution of the transplanted hPDCs to both the intermediate cartilage tissue as well as the bridging bone. A reduced contribution of the implanted cells was seen at week 8, suggesting that host-derived cells are involved in the remodeling of the newly formed bone tissue.

This study reports the development of a cell-based strategy for the healing of a critical size long-bone defect through a cartilaginous intermediate using a serum-free, chemically defined, and biomimetic approach. In vitro BMP-2 treatment of cell-based bioinspired engineered microtissues leads to a primed but not mature cartilage tissue, self-sustained by endogenous production of growth and differentiation factors. Upon in vivo implantation, tissue formation is achieved in a process mimicking natural fracture healing. Encouragingly, this approach is applicable for autologous as well as allogenic progenitor cell populations. The presented findings represent a fundamental contribution to the successful development of clinically relevant cell-based constructs for tissue regeneration and provide convincing information on the importance of relevant in vitro conditions for the in vivo outcome.

Experimental Procedures {#sec4}
=======================

Pre-conditioning in CDM or GM as a control was carried out for 6 days. Directly following pre-conditioning, BMP-2 stimulation and/or aggregation was carried out for an additional 6 days. In vivo implantation was carried out ectopically and orthotopically in NMRI^nu/nu^ mice. Cell material was encapsulated in collagen type 1 gels for implantation. In vivo development of the implanted constructs was studied for up to 8 weeks. Detailed experimental procedures are provided in the [Supplemental Information](#app2){ref-type="sec"}. The ethical committee for human medical research (KU Leuven) approved all procedures, and informed consent was obtained from the patients. All procedures on animal experiments were approved by the local ethical committee for animal research (KU Leuven). The animals were housed according to the guidelines of the Animalium Leuven (KU Leuven).
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![Serum-free Pre-conditioning for 6 Days Affected Cellular Identity\
(A) DNA quantification in cells pre-conditioned in CDM or GM normalized to day 0.\
(B--E) DNA per cell after 6 days of pre-conditioning (B). Pre-conditioning induced expression of cell cycle regulators *CDK1* (C), *CCNE1*(D), and *BIRC5* (E).\
(F) Flow cytometry analysis after pre-conditioning for MSC markers CD73, CD90, and CD105 together with CD34.\
(G and H) Kinetics studies on (G) the mRNA transcript level of *CD34* and (H) flow cytometry data on the number of CD34 molecules per cell.\
(I and J) Kinetic studies on (I) the mRNA transcript level of *CD105* and (J) flow cytometry data on the number of CD105 molecules per cell.\
(K--M) mRNA transcript analysis of BMP type 1 and type 2 receptors (K), *FGF2*, *VEGF*, and *MMP9* (L), confirmed on the protein level from conditioned medium (M).\
n = 3, ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.](gr1){#fig1}

![Serum-free Pre-conditioning led to Enhanced BMP-2-Induced Osteochondrogenic Differentiation In Vitro\
After 6 days of pre-conditioning followed by 6 days of BMP-2 stimulation in CDM, a difference in response to BMP-2 was observed.\
(A) Bright-field images after 6 days of BMP-2 stimulation indicating differentiated cells (black arrows).\
(B--E) BMP-2 stimulation induced elevated ALP activity(B). mRNA transcripts displayed elevated expression of *SOX9* (C), *OSX* (D), and *ID1* (E) after 24 hr, and 3 and 6 days of BMP-2 stimulation.\
(F) IHC for SOX9 (red) and OSX (green) with DAPI (blue) as nuclear stain after 6 days of BMP-2 stimulation.\
(G--J) Quantification of merged confocal images expressed as relative units (RU) normalized to DAPI (G). mRNA transcript analysis after pre-conditioning of hPDCs followed by 6 days of stimulation of BMP-2, -6, -7, -9, and GDF5 depicted by *SOX9* (H), *OSX* (I), and *ID1* (J). Scale bar, 50 μm; n = 3, ^∗/\#^p \< 0.05, ^∗∗/\#\#^p \< 0.01, ^∗∗∗/\#\#\#^p \< 0.001 where ^\#^ represents statistical significance to BMP-2 treated condition.](gr2){#fig2}

![Altered Pathway Activation upon Pre-conditioning with CD34^+^ Cells Displaying a More Potent Osteochondro-Progenitor Cell Population\
(A--J) Pathway activation following pre-conditioning and BMP-2 stimulation investigated by western blot and subsequent quantification for (A) and (F) p-SMAD1/5/8, (B) and (G) p-Erk1/2, (C) and (H) p-p38, (D) and (I) active β-catenin, and (E) and (J) p-SMAD2/3.\
(K and L) Following separation of the CD34^+^ cell population, elevated expression of CD34 (K) and BMP receptors (L) were seen.\
(M) Following 6 days of BMP-2 stimulation the CD34^+^ hPDCs showed elevated differentiation depicted by *SOX9* and *OSX* expression.\
(N) Cluster analysis displayed a correlation between the expression of CD34, BMP receptors, and differentiation markers.\
(O) A constellation plot showed clear grouping of CD34^+^ cells and the total cell population.\
n = 3, ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.](gr3){#fig3}

![The Number of Cells per Aggregate Affected Osteogenic and Chondrogenic Cell Specification\
To determine optimal size, aggregates of 50, 100, and 250 cells/aggregate were investigated after 6 days of aggregation.\
(A--D) Aggregation and BMP-2 stimulation induced a shift in MSC marker expression and a reduction when both factors were combined (A). mRNA transcript analysis of (B) chondrogenic, (C) osteogenic, and (D) BMP signaling and angiogenic markers indicated that both aggregation, aggregation size and BMP-2 stimulation affected cell differentiation. n = 3, statistical significance to non-BMP-2-stimulated conditions: ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001 and to 2D BMP-2 conditions: ^\#^p \< 0.05, ^\#\#^p \< 0.01, ^\#\#\#^p \< 0.001.](gr4){#fig4}

![In Vitro Priming Leads to an In Vivo Cartilage Intermediate 1 Week Post Transplantation\
Histology of tissue constructs 1 week after in vivo subcutaneous implantation displayed that both BMP-2 stimulation and aggregation affected in vivo tissue formation.\
(A) H&E staining showed microvessel formation (black arrows).\
(B and C) Denser AB staining revealed more cartilage matrix accumulation (black arrows) (B), confirmed by denser collagen staining by MT staining (black arrows) (C).\
(D) Upon IHC for p-SMAD1/5/8 as a marker for active BMP signaling, positive nuclei (brown stain, black arrows) were seen in samples stimulated by BMP-2 and/or aggregation.\
(E and F) Quantification showed that the combined stimulation of BMP-2 and aggregation elevated the number of microvessels (E) and positive nuclei for p-SMAD1/5/8 (F).\
(G) BMP-2 production by stimulated cells were confirmed in conditioned medium by ELISA.\
(H) Enhanced transcripts for *BMP-2* on implants at the time of implantation.\
Scale bars, 20 μm. n = 4, ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.](gr5){#fig5}

![The Combined In Vitro Priming by BMP-2 Treatment and Aggregation Led to Endochondral Bone Formation In Vivo\
Histology on tissue constructs 3 weeks after in vivo subcutaneous implantation demonstrated that the simultaneous stimulation by aggregation and BMP-2 affected in vivo tissue formation.\
(A) H&E staining displayed the presence hypertrophic chondrocytes (black arrows) next to denser ECM areas (white arrows).\
(B) Denser AB stain lines the zones of hypertrophic chondrocytes (white arrows) surrounded by GAG-rich areas (white arrows).\
(C) The MT stain confirmed the formation of denser areas (black arrows).\
(D and E) TRAP-positive areas (black arrows) surrounding the hypertrophic chondrocytes suggest remodeling (D) and quantification (E).\
(F) IHC for DIPEN showed breakdown of GAG-rich areas.\
(G and H) IHC for S100 displayed more mature cartilage tissue in BMP-2 stimulated aggregates (G), confirmed by quantification (H).\
(I and J) IHC for Ihh showed the presence of hypertrophic chondrocytes (I), which upon quantification was a 4-fold higher compared with 2D-stimulated cells (J).\
(K) At 6 weeks, the endochondral tissue intermediate had developed into a mineralized ossicle.\
(L) H&E staining confirmed de novo formed bone (black arrows) and bone marrow (red arrows), while MT staining displayed zones of mature bone (green arrows). TRAP staining suggested ongoing remodeling of immature bone (blue arrows) and IHC for hOCN confirmed the contribution of the implanted cells. Unlabeled scale bars, 20 μm. n = 4, ^∗^p \< 0.05, ^∗∗^p \< 0.01.](gr6){#fig6}

![The In Vitro Primed Cell-based Tissue Construct Led to the Healing of a Critical Size Long-Bone Defect\
(A) In vivo X-ray monitoring of fracture healing upon transplantation of in vitro BMP-2-stimulated microaggregates.\
(B) Reconstructed images from nano-computed tomography scanned explants displayed mineralized healing of the critical-sized defect 4 weeks post transplantation.\
(C--G) Qualitative analysis of sectioned explants 2, 4, and 8 weeks post transplantation, including control confirming non-union. Cartilage and bone formation was confirmed by H&E (C), Safranin O and fast green (D), and MT (E) staining. Tissue remodeling was investigated by a TRAP stain (F), whereas contribution of implanted cells was confirmed by IHC for hOCN (G). Arrows indicate specific tissues as follows: cartilage (gray), bone (black), mature bone (yellow), TRAP-positive areas (blue), hOCN-positive cells, and matrix (white). Unlabeled scale bar, 50 μm.](gr7){#fig7}
